Clearpoint Neuro, Inc. — 2013 Q3 10-Q Summary
Entity and period: The supplied filing is for MRI Interventions, Inc., for the quarter and nine months ended September 30, 2013. The filing does not identify the registrant as Clearpoint Neuro, Inc.; verify the entity match before relying on this summary.
Business context
MRI Interventions developed and commercialized the ClearPoint system for minimally invasive brain procedures guided by intra-procedural MRI. ClearPoint had U.S. FDA clearance and European CE marking. The ClearTrace cardiac system remained under development and had no regulatory clearance or product revenue. The company also had MRI-safety licensing and development arrangements with Boston Scientific.
Financial results and position
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Total revenue | $927,457 | $1,131,828 | $2,754,145 | $3,195,587 |
| Operating loss | $1,861,220 | $1,017,039 | $5,406,548 | $2,648,008 |
| Net loss | $3,194,812 | $2,761,293 | $5,370,492 | $6,835,661 |
| Net loss per share | $0.05 | $0.06 | $0.09 | $0.18 |
- Q3 product and service revenue rose 92% to about $927,000, led by ClearPoint product sales; total revenue fell because no Boston Scientific license revenue was recognized in Q3 2013.
- For the nine-month period, product and service revenue increased 69% to $2.1 million, while total revenue declined 14% as Boston Scientific license revenue fell from $1.95 million to $650,000. The license-fee recognition period ended March 31, 2013.
- Product revenue was $1.81 million for the nine months, up 117%; disposable-product sales rose with procedure volume. Management said product gross margin was relatively consistent year over year.
- Nine-month operating loss increased substantially, reflecting higher operating costs and the prior-year $883,000 reversal of an R&D obligation. Net loss nevertheless improved, in part because of a $1.33 million gain from remeasurement of warrant liabilities and lower interest expense; 2013 also included a $1.36 million loss on a loan modification.
- Cash and equivalents were $5.03 million at September 30, 2013, versus $1.62 million at December 31, 2012. Current assets were $7.23 million and current liabilities $6.31 million. Total liabilities were $15.13 million; stockholders’ deficit was $5.61 million.
- Nine-month operating cash use was $6.26 million, versus $5.21 million in 2012; investing cash use was $174,000. Financing provided $9.85 million, primarily from the January 2013 private placement, and cash increased $3.41 million.
- Debt included $4.34 million of related-party Boston Scientific convertible notes, a Brainlab note with $3.82 million carrying value, and junior secured notes with $218,000 carrying value. The Brainlab note was modified in March 2013, is due in April 2016, and bears 5.5% interest; the modification increased principal and removed its conversion feature.
Changes, outlook, and risks
- Management expected continued losses through at least year-end 2013 and said September-end cash, together with product and service receipts, should fund anticipated needs through at least March 2014. This was management’s estimate, not a guarantee.
- The company planned to increase sales and marketing spending during the remainder of 2013 to support ClearPoint commercialization. It said discretionary spending could be deferred and additional financing might be needed; financing could dilute shareholders, and availability on acceptable terms was uncertain.
- Important risks include uncertain ClearPoint market acceptance and reimbursement, dependence on expanding sales and clinical-support capabilities, reliance on some single-source suppliers, and the cost, timing, and regulatory uncertainty of developing ClearTrace.
- Summer Street Research Partners arbitration sought $480,000 in commissions and warrants for 460,338 shares. The company filed counterclaims, said the matter was preliminary and could not be reasonably estimated, and recorded no liability.
- The company identified prior warrant-accounting errors involving derivative liabilities and changed procedures to use a third-party specialist for complex financings and provide additional staff training. Management concluded disclosure controls were effective as of September 30, 2013.
- The company’s warrants were accounted for as derivative liabilities; their fair value was $4.11 million at quarter-end, with valuation dependent on significant unobservable inputs.
Important facts for investors to verify
- Confirm that this MRI Interventions, Inc. filing is the intended filing for Clearpoint Neuro, Inc.
- Assess cash burn against the stated March 2014 runway estimate, and determine whether additional financing was needed after the filing date.
- Track ClearPoint procedure volumes, disposable-product sales, and the cost of commercial expansion as license revenue phases out.
- Review debt terms and covenants, warrant-liability valuation and potential dilution, and the outcome of the Summer Street arbitration.
- Check progress, funding requirements, and regulatory plans for ClearTrace, and confirm the effectiveness of the revised accounting controls.